Potential use of mesenchymal stem cells in regenerative medicines: a review
View/ Open
Date
2022-08Publisher
Brac UniversityAuthor
Tisha, Nudrat TabassumMetadata
Show full item recordAbstract
The utilization of Mesenchymal Stem Cells (MSCs) in biomedicine has expanded dramatically
over the past 50 years. MSCs are a diverse group of cells, extracted from fat, synovium and bone
marrow with the ability to self-renew and differentiate into several types and thus can be utilized
for various biomedical applications. As MSCs do not express major histocompatibility
complexes or immune-stimulating molecules, they are not detected by the immune surveillance
system within a host body which prevents graft rejection after transplantation, thus making
MSCs an ideal candidate to be used as regenerative medicine. Unlike therapeutic approaches that
deliver a single agent at a fixed dose, MSCs produce bioactive chemicals and impulses that are
site controlled, adding to their advantage to be used for tissue engineering. More than 950
clinical trials are currently examining the potential medical benefits of MSCs for various
biomedical purposes, including regenerative medicine. Development of new approaches to
comprehend and unleash the potential of MSCs, as well as new delivery modalities and patient
selection, should lead to significant breakthroughs in the future years and more therapeutic
opportunities for MSCs in the field of regenerative medicine. The present review aims to provide
a comprehensive overview of the preclinical and clinical applications of MSCs in regenerative
medicine and further discuss the challenges associated with developing MSCs for regenerative
medicine with future prospects.